Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study

Blood

Volumn 90, Issue 4, 1997, Pages 1656-1663

  Gallagher, Robert E ^a   Willman, Cheryl L ^b   Slack, James L ^b   Andersen, Janet W ^b   Li, Yun Ping ^b   Viswanatha, David ^b   Bloomfield, Clara D ^b   Appelbaum, Frederick R ^b   Schiffer, Charles A ^b   Tallman, Martin S ^b   Wiernik, Peter H ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE FUSION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; CLONING, MOLECULAR; EXONS; HEMOGLOBINS; HUMANS; INTRONS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PLATELET COUNT; PROGNOSIS; RNA, MESSENGER; TREATMENT OUTCOME; TRETINOIN;

EID: 0030812198     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG: Acute promyelocytic leukemia: From genetics to treatment. Blood 83:10, 1994
2. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A: The PML-RARα fusion mRNA generated by the t(15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675, 1991
3. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VVVS, Dmitrovsky E, Evans RM: Chromosomal translocation t(15; 17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66:663, 1991
4. Pandolfi PP, Alcalay M, Fagioli M, Zangrilli D, Mencarelli A, Diverio D, Biondi A, Lo Coco F, Rambaldi A, Grignani F, Rochette-Egly C, Gaub M-P, Chambon P, Pelicci PG: Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/RARα isotbrms in acute promyelocytic leukaemia. EMBO J 11:1397, 1992
5. Chen S-J. Chen Z, Chen A, Tong J-H, Dong S, Wang Z-Y, Waxman S, Zelent A: Occurrence of distinct PML-RARα fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction. Oncogene 7:1223, 1992
6. Miller WH Jr, Kakizuka A, Frankel SR, Warrell RP Jr, De-Blasio A, Levine K, Evans RM, Dmitrovsky E: Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor-α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:2694, 1992
7. Fukutani H, Naoe T, Yoshida H, Yamamori S, Ohno R: Molecular heterogeneity of the PML gene rearrangement in acule promyelocytic leukemia: Prevalence and clinical significance. Jpn J Cancer Res 84:257, 1993
8. Gallagher RE, Li Y-P, Rao S, Paietta E, Andersen J, Etkind P, Tallman MS, Wiernik PH: Characterization of acute promyelocytic leukemia cases with PML-RARα break/fusion sites in PML exon 6: Identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 86:1540, 1995
9. Breitman TR, Collins SJ, Keene BR: Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 57:1000, 1981
10. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L: All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: Structure-function relationship. Blood 76:1710, 1990
11. Elliott S, Taylor K, White S, Rodwell R, Marlton P, Meagher D, Wiley J, Taylor D, Wright S, Timms P: Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 79:1916, 1992
12. Kastner P, Perez A, Lutz Y, Rochette-Egly C, Gaub M-P, Durand B, Lanotte M, Berger R, Chambon P: Structure, localization and transcriptional properties of two classes of retinoic acid receptor α fusion proteins in acute promyelocytic leukemia (APL): Structural similarities with a new family of oncoproteins. EMBO J 11:629, 1992
13. Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P: PMLRAR homodimers: Distinct DNA binding properties and heterodimeric interactions with RXR. EMBO J 12:3171, 1993
14. Tallman MS, Andersen J, Schiffer CA, Appelbaum FR, Feusner JE, Woods WG, Ogden A, Weinstein H, Shepherd L, Rowe JM, Wiernik PH: Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia. Blood 86:125, 1995 (suppl 1)
15. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman CL, Bloomfield CD, Rowe JM, Wiernik PH: A prospective randomized study of all-trans retinoic acid induction and maintenance therapy for patients with acute promyelocytic leukemia. (submitted for publication)
16. Borrow J, Goddard AD, Gibbons B, Katz F, Swirsky D, Fioretos T, Dube I, Winfield DA, Kingston J, Hagemeijer A, Rees JKH, Lister TA, Solomon E: Diagnosis of acute promyelocytic leukaemia by RT-PCR detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 82:529, 1992
17. Huang W, Sun G-L, Li X-S, Cao Q, Lu Y, Jang G-S, Zhang F-Q, Chai J-R, Wang Z-Y, Waxman S, Chen Z, Chen S-J: Acute promyelocytic leukemia: Clinical relevance of two major PMLRARα isoforms and detection of minimal residual disease by retro-transcriptase/polymerase chain reaction to predict relapse. Blood 82:1264, 1993
18. Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, Warrell RP Jr: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843, 1994
19. Fukutani H, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, Miyake T, Nakayama Y, Kobayashi H, Goto S, Takeshita A, Kobayashi S, Kato Y, Shiraishi K, Sasada M, Ohtake S, Murakami H, Kobayashi M, Endo N, Shindo H, Matusushita K, Hasegawa S, Tsuji K, Ueda Y, Tominaga N, Furuya H, Inoue Y, Takeuchi I, Morishita H, Iida H: Isoforms of PML-retinoic acid alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. Leukemia 9:1478, 1995
20. Boyum A: Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest 21:1, 1968
21. Chirgwin J, Przybyla A, MacDonald R, Rutter RJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294, 1979
22. Chomczynski P, Sacchi N: Method for rapid isolation of total cellular RNA by guanidine isothiocyanate in acidic phenol. Anal Biocem 162:156, 1987
23. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP: Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad. Sci USA 85:5698, 1988
24. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 40:819, 1984
25. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
26. Cox DR, Oakes D: Analysis of Survival Data. New York, NY, Chapman and Hall, 1984
27. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
28. Lehmann E: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA, Holden-Day, 1975
29. Fenaux P, Le Deley MC, Castaigne S: Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomization trial. Blood 82:3241, 1993
30. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de The H: The t(15; 17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 13:1073, 1994
31. Dyck JA, Maul GG, Miller WH Jr, Chen JC, Kakizuka A, Evans RM: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333, 1994
32. Weis K, Rambaud S, Laqvau C, Jansen J, Carvalgo T, Carmo-Fonseca M, Lamond A, Dejean A: Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocyte leukemia. Cell 76:345, 1994
33. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol 44:169, 1980
34. Biondi A, Luciano A, Bassan R, Mininni D, Specchi G, Lanzi E, Castagna S, Cantu-Rajnoldi A, Liso B, Masera G, Barbui T, Rambaldi A: CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. Leukemia 9:1461, 1995
35. Maslak P, Miller WH Jr, Scheinberg DA, Dmitrovsky E, Warrell RP Jr: CD2 expression and PML/RARα transcripts in acute promyelocytic leukemia. Blood 81:1666, 1993
36. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD: Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood 73:1116, 1989
37. Davey FR, Davis RB, MacCallum JM, Nelson DA, Mayer RJ, Ball ED, Griffin JD, Schiffer CA, Bloomfield CD: Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol 30:221, 1989
38. Fenaux P, Pollet J, Vandenbossche-Simon L, Morel P, Zandecki M, Jouet J, Bauters F: Treatment of acute promyelocytic leukemia: A report of 70 cases. Leuk Lymphoma 4:239, 1991
39. Head D, Kopecky K, Weick J, Files J, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Willman C, Appelbaum F: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717, 1995
40. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Guerci A, Maloissel F, Bordenoule D, Sadoun A, Tiberghien P, Feguex N, Daniel MT, Chomienne C, Degos L: All trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 80:2176, 1992
41. Ohno R, Yoshida H, Fukutani H, Naoe T, Ohshima T, Kyo T, Endoh N, Fujimoto T, Kobiyashi T, Hiraoka A, Mizoguchi H, Kodera Y, Suzuki H, Hirano M, Akiyama H, Aoki N, Shindo H, Yokomaku S: Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 7:1722, 1993
42. Frankel SR, Eardley A, Heller G, Berman E, Miller Jr WH, Dmitrovsky E, Warrell RP Jr: All-trans-retinoic acid for acute promyelocytic leukemia: Results of the New York study. Ann Int Med 120:278, 1994
43. Slack JL, Willman CL, Li Y-P, Viswanatha D, Bloomfield CD, Wiernik PH, Tallman MS, Gallagher RE: Molecular characteristics and clinical features of adult APL patients with the type V PML-RARα-isoform: Results from intergroup protocol 0129. Blood 88:635, 1996 (suppl 1)
44. Diverio D, Pandolfi PP, Rossi V, Biondi A, Pelicci PG, Lo Coco F: Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. Leukemia 8:1105, 1994